Skip to main content
Richard Willett on Muck Rack

Richard Willett

Norwich
As seen in: David Icke, Patreon, Substack, Activist Post, Kirkus Reviews, SGT Report, New Jersey Stage
Filmmaker, Journalist, Presenter, Author PATREON, ICKONIC.COM www.patreon.com/cw/RichardWillett NEW BOOK OUT NOW! amzn.eu/d/0cdZVmWQ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

HUBBARD & EPSTEIN: THE IMMORTALITY SCAM

|
By Richard Willett
| Substack
I have recently been researching the background of L Ron Hubbard of Scientology fame. Despite what the official words of Scientology claim, this was not only deeply depraved man but also a chronic liar. L Ron Hubbard was the P T Barnum of pseudo-psychoanalytic bullshit, and that was only towards the end of his life. His early years were littered with scams and lies involving his ‘heroic’ adventures that only existed in his hyper vigilant mind.
Open in Who Shared Issue with article?

Richard Willett (@richardwillett)

|
By Richard Willett
| Substack
Make money doing the work you believe in Start your SubstackLearn more
Open in Who Shared View Duplicates (20) Issue with article?

Insilico Medicine advances AI drug for IPF to Phase III trials

|
By Richard Willett, David Icke
| David Icke
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety evaluations into late-stage efficacy validation. IPF destroys respiratory capacity through severe lung tissue scarring. Patients typically present a median survival rate reaching two to four years post-diagnosis.
Open in Who Shared Issue with article?
See all 2,827 articles